AIP26GQ-FITC

AIP26GQ-FITC is a preclinical-stage adapter molecule developed by AI Proteins in collaboration with Bristol Myers Squibb for the treatment of acute myeloid leukemia (AML). It consists of a de novo designed, AI-engineered 5.6 kDa miniprotein (AIP26GQ) conjugated to fluorescein isothiocyanate (FITC) via an engineered lysine residue. The miniprotein component binds with exceptionally high affinity (KD = 0.5 pM) to CD123 (IL-3 receptor alpha chain) on the surface of tumor cells. Functioning as part of a modular CAR-T system, the FITC moiety serves as a recruitment tag for anti-FITC CAR-T cells, directing their cytotoxic activity specifically toward CD123-expressing cancer cells. In preclinical models, AIP26GQ-FITC has demonstrated the ability to reduce tumor burden to background levels and maintain stable remission.